

## MRD Testing Implementation Roadmap for Blood Cancers: Post-Assessment

Thank you for taking the Measurable Residual Disease (MRD) Testing Implementation Roadmap for Blood Cancers: Post-Assessment.

Before you begin this post-assessment, we encourage you to review and discuss it with the core team members for your initiative. This post-assessment can be used to help you evaluate the outcomes of your initiative and identify opportunities for improvement.

This post-assessment will take approximately 5 minutes to complete. **Please be sure to <u>submit your</u>** responses electronically.

Data collected as part of this post-assessment will help ACCC learn about MRD testing for adult blood cancers in cancer programs across the country and will inform improvements to the MRD Testing Implementation Roadmap. Data may be presented (aggregated and de-identified) in ACCC publications.

1.	What is the name of your organization? (No abbreviations please.)
2.	Please list the names and titles of individuals that were members of your core team for this initiative, including the Project Champion.
3.	Does your organization currently conduct MRD testing in clinical practice for adult blood cancers?  Yes No (if no, please go to question 6)
4.	Approximately what percentage of your adult patients with blood cancers currently undergo MRD testing?
	<ul><li>AML</li><li>B-cell ALL</li></ul>
	• CLL
	Multiple Myeloma
	• Other

5.	Please briefly describe when/under what circumstances your organization conducts MRD testing
	for adult patients with blood cancers?

6. Please indicate your level of agreement with the following statements.

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Our organization has a multidisciplinary team committed to planning and implementing MRD testing for adult patients with blood cancers.					
Our organization's clinical and support staff understand MRD testing methods for adult patients with blood cancers.					
Our organization's clinical and support staff understand the benefits of MRD testing for adult patients with blood cancers.					
Our organization has integrated MRD testing into our clinical information systems (e.g., EMR) and clinical workflows.					
Our organization would recommend the MRD Testing Implementation Roadmap to other organizations looking to implement or expand MRD testing for adult patients with blood cancers.					